HK1167005A1 - K-ras and b-raf mutations and anti-egfr antibody therapy k-ras - Google Patents

K-ras and b-raf mutations and anti-egfr antibody therapy k-ras

Info

Publication number
HK1167005A1
HK1167005A1 HK12107511.1A HK12107511A HK1167005A1 HK 1167005 A1 HK1167005 A1 HK 1167005A1 HK 12107511 A HK12107511 A HK 12107511A HK 1167005 A1 HK1167005 A1 HK 1167005A1
Authority
HK
Hong Kong
Prior art keywords
ras
egfr antibody
antibody therapy
raf mutations
raf
Prior art date
Application number
HK12107511.1A
Other languages
English (en)
Inventor
Salvatore Siena
Alberto Bardelli
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39666021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1167005(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1167005A1 publication Critical patent/HK1167005A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12107511.1A 2007-03-13 2010-05-17 K-ras and b-raf mutations and anti-egfr antibody therapy k-ras HK1167005A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90697607P 2007-03-13 2007-03-13

Publications (1)

Publication Number Publication Date
HK1167005A1 true HK1167005A1 (en) 2012-11-16

Family

ID=39666021

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12107511.1A HK1167005A1 (en) 2007-03-13 2010-05-17 K-ras and b-raf mutations and anti-egfr antibody therapy k-ras

Country Status (20)

Country Link
US (2) US20090075267A1 (hr)
EP (2) EP2412828B1 (hr)
JP (3) JP2010521154A (hr)
AR (1) AR065686A1 (hr)
AU (1) AU2008226808B2 (hr)
CA (1) CA2680330A1 (hr)
CL (1) CL2008000716A1 (hr)
CY (1) CY1114159T1 (hr)
DK (1) DK2412828T3 (hr)
ES (1) ES2426814T3 (hr)
HK (1) HK1167005A1 (hr)
HR (1) HRP20130764T1 (hr)
MX (1) MX2009009779A (hr)
PE (1) PE20090690A1 (hr)
PL (1) PL2412828T3 (hr)
PT (1) PT2412828E (hr)
RS (1) RS52932B (hr)
SI (1) SI2412828T1 (hr)
TW (1) TW200904828A (hr)
WO (1) WO2008112274A2 (hr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
ITBO20050646A1 (it) 2005-10-26 2007-04-27 Silicon Biosystem S R L Metodo ed apparato per la caratterizzazione ed il conteggio di particelle
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
SI2412828T1 (sl) * 2007-03-13 2013-10-30 Amgen Inc. Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr
PL2121989T5 (pl) * 2007-03-13 2023-03-06 Amgen Inc. Mutacje K-RAS oraz terapia przeciwciałem anty-EGFR
ITTO20070771A1 (it) 2007-10-29 2009-04-30 Silicon Biosystems Spa Metodo e apparato per la identificazione e manipolazione di particelle
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US10895575B2 (en) 2008-11-04 2021-01-19 Menarini Silicon Biosystems S.P.A. Method for identification, selection and analysis of tumour cells
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
EP3722810A3 (en) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molecular profiling of tumors
CN101487051B (zh) * 2009-02-24 2011-07-20 广州益善生物技术有限公司 Braf基因突变的检测探针、液相芯片及其检测方法
DK2408562T3 (en) 2009-03-17 2018-06-06 Menarini Silicon Biosystems Spa Microfluidic device for isolating cells
WO2011028540A1 (en) * 2009-08-24 2011-03-10 Genentech, Inc. Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
WO2011031840A1 (en) * 2009-09-09 2011-03-17 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
US20110217309A1 (en) * 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
JP2013523178A (ja) * 2010-04-12 2013-06-17 レスポンス ジェネティクス，インコーポレイティド Ｋｒａｓプライマーおよびプローブ
CA2804335A1 (en) 2010-06-15 2011-12-22 Alberto Bardelli Mlk4 gene, a new diagnostic and prognostic marker in cancers
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
WO2012049279A1 (en) 2010-10-14 2012-04-19 Universitaet Des Saarlandes MEANS AND METHODS APPLYING SINGLE NUCLEOTIDE PRIMER EXTENSION WITH ION PAIR-, REVERSED-PHASE HPLC (SIRPH) FOR THE DIAGNOSIS OF SNPs
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
ITTO20110990A1 (it) 2011-10-28 2013-04-29 Silicon Biosystems Spa Metodo ed apparato per l'analisi ottica di particelle a basse temperature
US9023640B2 (en) * 2011-12-13 2015-05-05 Fundamental Solutions Corporation Device for rapid detection of infectious agents
BR112015003418A2 (pt) 2012-08-17 2017-07-04 Hoffmann La Roche produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
JP6520705B2 (ja) * 2013-03-19 2019-05-29 凸版印刷株式会社 Ｅｇｆｒ阻害剤感受性予測方法
JP6512828B2 (ja) 2014-01-07 2019-05-15 三星電子株式会社Ｓａｍｓｕｎｇ Ｅｌｅｃｔｒｏｎｉｃｓ Ｃｏ．，Ｌｔｄ． ｃ−Ｍｅｔ阻害剤の効能予測または効能検証のためのバイオマーカー
WO2015175705A1 (en) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
KR20160037666A (ko) 2014-09-29 2016-04-06 삼성전자주식회사 KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측
US10471183B2 (en) 2015-12-22 2019-11-12 Access Vascular, Inc. High strength biomedical materials
US11577008B2 (en) 2017-06-21 2023-02-14 Access Vascular, Inc. High strength porous materials incorporating water soluble polymers
CN107918013A (zh) * 2017-09-25 2018-04-17 浙江天科高新技术发展有限公司 化学发光酶免测定循环肿瘤细胞中K‑Ras蛋白的方法及试剂盒
CN108085390A (zh) * 2017-12-29 2018-05-29 上海桐树生物科技有限公司 肿瘤驱动基因变异的检测剂、检测试剂盒及其应用
EP4171704A1 (en) 2020-06-30 2023-05-03 Access Vascular, Inc. Articles comprising markings and related methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1161563A2 (en) 1999-03-15 2001-12-12 PE Corporation (NY) Probe/mobility modifier complexes for multiplex nucleic acid detection
EP1313880A2 (en) 2000-05-30 2003-05-28 PE Corporation (NY) Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
MXPA04011550A (es) 2002-05-20 2005-02-17 Abgenix Inc Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico.
ES2741574T3 (es) * 2004-03-31 2020-02-11 Massachusetts Gen Hospital Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
JP2008535477A (ja) 2005-02-24 2008-09-04 アムジエン・インコーポレーテツド 上皮成長因子受容体変異
JP2008536493A (ja) * 2005-04-01 2008-09-11 アムジエン・インコーポレーテツド 上皮増殖因子受容体遺伝子のコピー数
BRPI0610440A2 (pt) * 2005-04-14 2010-06-22 Merck Patent Gmbh terapia com anticorpo anti-egfr baseada em um maior número de cópias do gene egfr em tecidos de tumores
JP2008546421A (ja) * 2005-06-28 2008-12-25 ジェネンテック・インコーポレーテッド Ｅｇｆｒおよびｋｒａｓ変異
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
CN101501803B (zh) * 2006-08-10 2011-08-03 株式会社生方制作所 热响应开闭器
SI2412828T1 (sl) * 2007-03-13 2013-10-30 Amgen Inc. Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr
PL2121989T5 (pl) * 2007-03-13 2023-03-06 Amgen Inc. Mutacje K-RAS oraz terapia przeciwciałem anty-EGFR

Also Published As

Publication number Publication date
EP2412828B1 (en) 2013-06-05
RS52932B (en) 2014-02-28
TW200904828A (en) 2009-02-01
DK2412828T3 (da) 2013-09-02
AR065686A1 (es) 2009-06-24
CL2008000716A1 (es) 2008-09-22
EP2412828A1 (en) 2012-02-01
WO2008112274A2 (en) 2008-09-18
AU2008226808A1 (en) 2008-09-18
CY1114159T1 (el) 2016-08-31
EP2118322A2 (en) 2009-11-18
SI2412828T1 (sl) 2013-10-30
ES2426814T3 (es) 2013-10-25
CA2680330A1 (en) 2008-09-18
JP2013253105A (ja) 2013-12-19
JP5905422B2 (ja) 2016-04-20
JP2015119726A (ja) 2015-07-02
PE20090690A1 (es) 2009-06-22
US20090075267A1 (en) 2009-03-19
MX2009009779A (es) 2009-09-23
HRP20130764T1 (hr) 2013-10-25
JP2010521154A (ja) 2010-06-24
PL2412828T3 (pl) 2013-11-29
PT2412828E (pt) 2013-08-02
US20110212456A1 (en) 2011-09-01
AU2008226808B2 (en) 2013-04-18
WO2008112274A3 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
HK1167005A1 (en) K-ras and b-raf mutations and anti-egfr antibody therapy k-ras
SI2121989T1 (sl) Mutacije k-ras in terapija s protitelesi anti-egfr
HK1136822A1 (en) Therapeutic compounds and their use in cancer
ZA200905886B (en) Methods and kits for administering probiotics
EP2202913A4 (en) USER AUTHENTICATION SYSTEM AND METHOD THEREOF
GB0719644D0 (en) Therapeutic compounds and their use
EP2300011A4 (en) METHODS AND THERAPEUTIC COMPOUNDS
GB0724251D0 (en) Therapeutic compounds and their use
EP2004637A4 (en) SUBSTITUTED RING-CONDENSED AZINES AND THEIR USE IN CANCER THERAPY
EP2237792A4 (en) ANTI-C35 ANTIBODY COMBINATION THERAPIES AND METHODS
GB0807018D0 (en) Antibodies and treatment
GB2460178B (en) Depsipeptides and their therapeutic use
GB0607946D0 (en) Mono and combination therapy
GB0607949D0 (en) Mono and combination therapy
GB2460181B (en) Depsipeptides and their therapeutic use
HK1152038A1 (en) Azetidine derivatives, their preparation and their application in therapy
EP2097085A4 (en) THERAPEUTIC MATERIALS AND METHOD
EP2142648A4 (en) SCREENING AND ANTI-NSCLC THERAPEUTIC METHOD TARGETING THE CDCA8-AURKB COMPLEX
GB2460180B (en) Depsipeptides and their therapeutic use
EP2234667A4 (en) DETERMINATION AND METHODS OF ADMINISTERING A TREATMENT
GB0818663D0 (en) Gene regulation and its use in therapy
GB0705517D0 (en) Therapeutic compounds and their use
GB0819103D0 (en) Raphaine compounds and their use in therapy
GB0809326D0 (en) Depsipeptides and their therapeutic use
GB0809324D0 (en) Depsipeptides and their therapeutic use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170311